Biomedicine
Petrelintide: keep Week 28 separate from Week 42
FierceBiotech reported phase 2 results for Roche and Zealand’s investigational amylin analog. The middle-dose result and the previously promoted later endpoint answer different questions.
The report puts Week 28 mean weight loss at 9.8% with 5 mg versus 1.7% with placebo: an 8.1-percentage-point difference. The 7 mg and 9 mg groups reached 9.3% and 9.4%; higher doses did not produce greater loss in this analysis.
Zealand describes a randomized, blinded dose-finding study alongside diet and activity measures. Week 28 was the primary endpoint. Its release emphasizes up to 10.7% at Week 42 under the efficacy estimand, versus up to 10.2% under a policy estimand handling discontinuation differently.
FierceBiotech reports nausea in 20% of treated participants versus 6% on placebo. Zealand’s favorable vomiting and gastrointestinal-discontinuation statement concerns the maximally effective dose, not every dose pooled.
Phase 3 has begun, but this remains investigational. We read the release and reporting, not the full paper. These results cannot establish long-term benefit or rank drugs across different trials.
Sources and further reading
Post and cited sources reviewed in this batch